CRG-B191 / CorreGene - LARVOL DELTA

Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. (PubMed, Invest Ophthalmol Vis Sci) - "No significant immune response or retinal toxicity was observed in either preclinical models or the treated patient. cceAAV-aflibercept-Fc-YTE (F-CRG-B191) is a promising gene therapy candidate for nAMD, demonstrating potent anti-VEGF efficacy, durable therapeutic effects, and favorable safety profiles in both preclinical and early clinical settings."

First-in-human • Journal • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration